Collegium provides 2025 guidance: product revenue $735M-$750M, adj EBITDA $435M-$450M

COLLEGIUM PHARMACEUTICAL, INC

Product revenues, net expected $735M-$750M for 2025.
Jornay PM net revenue expected >$135M in 2025.
Adjusted EBITDA (excl. SBC) expected $435M-$450M.
Adjusted operating expenses (excl. SBC) expected $220M-$230M.
Repurchased $60M in shares in 2024 under $150M buyback program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.